阿立哌唑是解开神经性厌食症之谜的关键吗？：病例系列
Is aripiprazole a key to unlock anorexia nervosa?: A case series.
作者信息
Tahıllıoğlu Akın, Özcan Tuğçe, Yüksel Gamze, Majroh Noorjahan, Köse Sezen, Özbaran Burcu
机构信息
Department of Child and Adolescent Psychiatry Faculty of Medicine Ege University Izmir Turkey.
出版信息
Clin Case Rep. 2020 Sep 6;8(12):2827-2834. doi: 10.1002/ccr3.3271. eCollection 2020 Dec.
Abstract
Aripiprazole contributes an increase in body mass index and attenuation in anorexia nervosa (AN) symptoms, leading clinical improvements with lower side-effect profile; but it is not enough to cure comorbid depressive symptoms in AN.
摘要
阿立哌唑有助于增加体重指数并减轻神经性厌食症（AN）症状，带来临床改善且副作用较小；但它不足以治愈AN患者的共病抑郁症状。
相似文献
1
Is aripiprazole a key to unlock anorexia nervosa?: A case series.
Clin Case Rep. 2020 Sep 6;8(12):2827-2834. doi: 10.1002/ccr3.3271. eCollection 2020 Dec.
2
The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.
Int J Eat Disord. 2017 Apr;50(4):447-450. doi: 10.1002/eat.22704. Epub 2017 Mar 23.
3
Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure.
Eat Weight Disord. 2007 Sep;12(3):e54-7. doi: 10.1007/BF03327643.
4
Deep brain stimulation of the subcallosal cingulate for treatment-refractory anorexia nervosa: 1 year follow-up of an open-label trial.
Lancet Psychiatry. 2017 Apr;4(4):285-294. doi: 10.1016/S2215-0366(17)30076-7. Epub 2017 Feb 24.
5
Depressive symptoms and weight change in inpatients with anorexia nervosa: A cross-lagged panel model.
J Psychosom Res. 2023 Sep;172:111391. doi: 10.1016/j.jpsychores.2023.111391. Epub 2023 May 30.
6
A retrospective case series of electroconvulsive therapy in the management of comorbid depression and anorexia nervosa.
Int J Eat Disord. 2020 Feb;53(2):210-218. doi: 10.1002/eat.23181. Epub 2019 Oct 22.
7
A case series investigation of association between co-morbid psychiatric disorder and the improvement in body mass index among patients with anorexia nervosa and eating disorder not otherwise specified of the anorexia nervosa type.
J Eat Disord. 2015 Mar 26;3:10. doi: 10.1186/s40337-015-0049-z. eCollection 2015.
8
Prevalence of abnormal liver function tests and comorbid psychiatric disorders among patients with anorexia nervosa and eating disorders not otherwise specified in the anorexia nervosa DSM-IV criteria.
Singapore Med J. 2015 Sep;56(9):488-92. doi: 10.11622/smedj.2015132.
9
Focal psychodynamic therapy, cognitive behaviour therapy, and optimised treatment as usual in female outpatients with anorexia nervosa (ANTOP study): 5-year follow-up of a randomised controlled trial in Germany.
Lancet Psychiatry. 2022 Apr;9(4):280-290. doi: 10.1016/S2215-0366(22)00028-1. Epub 2022 Mar 13.
10
Pre-treatment attachment anxiety predicts change in depressive symptoms in women who complete day hospital treatment for anorexia and bulimia nervosa.
Psychol Psychother. 2015 Mar;88(1):54-70. doi: 10.1111/papt.12028. Epub 2014 Apr 9.
引用本文的文献
1
Use of atypical antipsychotics in individuals with anorexia nervosa.
Ment Health Clin. 2025 Feb 3;15(1):1-8. doi: 10.9740/mhc.2025.02.001. eCollection 2025 Feb.
2
Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study.
BMC Psychiatry. 2024 Nov 7;24(1):779. doi: 10.1186/s12888-024-06215-y.
3
Pharmacological Studies in Eating Disorders: A Historical Review.
Nutrients. 2024 Feb 22;16(5):594. doi: 10.3390/nu16050594.
4
An overview of the treatment of eating disorders in adults and adolescents: pharmacology and psychotherapy.
Postep Psychiatr Neurol. 2023 Mar;32(1):40-48. doi: 10.5114/ppn.2023.127237. Epub 2023 May 8.
5
Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review.
PLoS One. 2023 Mar 16;18(3):e0278189. doi: 10.1371/journal.pone.0278189. eCollection 2023.
6
Antipsychotics in the Treatment of Children and Adolescents with Anorexia Nervosa: A Systematic Review.
Biomedicines. 2022 Dec 7;10(12):3167. doi: 10.3390/biomedicines10123167.
7
The Rise and Fall of Dopamine: A Two-Stage Model of the Development and Entrenchment of Anorexia Nervosa.
Front Psychiatry. 2022 Jan 11;12:799548. doi: 10.3389/fpsyt.2021.799548. eCollection 2021.
8
From Desire to Dread-A Neurocircuitry Based Model for Food Avoidance in Anorexia Nervosa.
J Clin Med. 2021 May 21;10(11):2228. doi: 10.3390/jcm10112228.
本文引用的文献
1
Anorexia Nervosa and Comorbid Psychopathology.
Endocr Metab Immune Disord Drug Targets. 2018;18(4):316-324. doi: 10.2174/1871530318666180213111637.
2
Treatment of eating disorders in child and adolescent psychiatry.
Curr Opin Psychiatry. 2017 Nov;30(6):438-445. doi: 10.1097/YCO.0000000000000357.
3
Schizophrenia and anorexia nervosa - reciprocal relationships. A literature review.
Psychiatr Pol. 2017 Apr 30;51(2):261-270. doi: 10.12740/PP/OnlineFirst/63514. Epub 2016 Sep 15.
4
Outcome, comorbidity and prognosis in anorexia nervosa.
Psychiatr Pol. 2017 Apr 30;51(2):205-218. doi: 10.12740/PP/64580.
5
Anorexia Nervosa/Atypical Anorexia Nervosa.
Curr Probl Pediatr Adolesc Health Care. 2017 Apr;47(4):70-84. doi: 10.1016/j.cppeds.2017.02.003.
6
Classics in Chemical Neuroscience: Aripiprazole.
ACS Chem Neurosci. 2017 Jun 21;8(6):1135-1146. doi: 10.1021/acschemneuro.7b00087. Epub 2017 Apr 13.
7
The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.
Int J Eat Disord. 2017 Apr;50(4):447-450. doi: 10.1002/eat.22704. Epub 2017 Mar 23.
8
Association of Elevated Reward Prediction Error Response With Weight Gain in Adolescent Anorexia Nervosa.
Am J Psychiatry. 2017 Jun 1;174(6):557-565. doi: 10.1176/appi.ajp.2016.16060671. Epub 2017 Feb 24.
9
The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.
CNS Drugs. 2016 May;30(5):419-42. doi: 10.1007/s40263-016-0335-6.
10
The Perfect Storm - A Bio-Psycho-Social Risk Model for Developing and Maintaining Eating Disorders.
Front Behav Neurosci. 2016 Mar 10;10:44. doi: 10.3389/fnbeh.2016.00044. eCollection 2016.
Zotero 插件